Curis | CRIS - Operating Expenses


Curis reported $9.02M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 10.33B 126M Dec/2025
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Curis USD 9.02M 23.01M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Takeda JPY 1.02T 400.98B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Verastem USD 59.01M 21.98M Dec/2025
Xoma USD 22.84M 1.67M Sep/2024